Clinical trial
Open-Label Study of Intramuscular Olanzapine Depot in Patients With…
NCT00088465 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00088465 |
|---|---|
| Title | Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder |
| Official title | An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenic Disorders, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Intramuscular olanzapine depot |
| Enrollment | 931 |
| Start date | Aug 1, 2004 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jul 27, 2004 |
| Last update posted | Jan 11, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Croatia, Czechia, France, Germany, Hungary, Israel, Italy and 13 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: